Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning,
We've seen a nice 50% plus move in Cimatron (CIMT) since I recommended it late summer at $6. It spiked over $9.50 yesterday but I'm not a fan of how it spiked up and came back down on the day. So, if you're very sensitive to the short term, taking some profits here above $8.50 is a good idea. I think it goes double digits soon but a pull back to the high $7's could happen here first allowing it to cool off before another move higher.
On DIDG, plain and simple....I am Loading the Boat! We have a 13D filing that is real but the company has yet to elaborate due to the holidays most likely. I think it's Very likely they say more about Stuart Subotnick's involvement very soon and the stock will pick up newsletter and other coverage as we get into January. I think 10-15 cents is still quite likely. After meeting with the people behind the company in Los Angeles, I also think there's a significant chance the company is acquired in the first half of 2014.
DIDG is my top pick for the shorter term (30-90 days) as the upside is significant. Wise investors should be adding on this pull back around 4 cents as I would not be surprised to see Subotnick ramp up his position by buying in the open market early in 2014. If he decides to double down, we're talking 8-10MM shares in the market which would take this to a dime alongside other investor interest.
I believe many other investors will buy regardless once the company elaborates on his involvement. Quite a penny stock special situation in my opinion.
Cheers,
Sherlock
I think iCo Therapeutics will see a busy 2014 ahead, with both primary end data and HIV results coming in the first Half of next year.
Not too many followers in the US suggests that whilst the stock is currently undervalued, once discovered, those in already will get even better rewarded.
Q1 should see a nice run towards primary efficacy data from Phase 2.
Good luck to all of you in,
MMN
I do not get what is wrong with many on this board. Here is what happened today, P&D.com knew of MDDD's promo and used that to scare the crap out of people, so they issued an article that trashes the Company. So both P&D and the promo guys have skin but they want the opposite thing, I do not see that different to any stock out there on the OTCB.
What people fail to get is that there is money to be made on this one, cause the promo is not one day and the poster that stated that being above a buck would mean that triple digit gains is correct.
Play this for what it is. It has great volume and the sector is hot.
Actual float as per RBC is 131m shares. If you look at the number of shares that was given to fund the Company's operations last year, you will understand that many suppliers of the Company took shares for service/product.
Most suppliers were given shares at 1.3 to 2.4 cents. However, I imagine many would sell whenever their shares become free as they need the cash and may not care for investing in the Company.
The good news is that many shares were cleaned up last week. In addition, I believe 80 million of the current float is between insiders and close groups.
MMN
Abondanceinvest,
I like your enthusiasm about BISU and I truly hope this works out. However, I am not sure this last week gives investors support that this will hot 10 cents+.
I know lots of suppliers sold into last week, as they needed to, so I am hoping for an uptick next week and a touch back to 2 cents.
Any thoughts?
MMN
Surf,
I took some off the table, but that is logical since I have still the PP coming and the warrants as well.
I do not want to be pounding the table in Q3 2010 when/if this goes back down, as it did in 2008.
MMN
Guys,
Canacord buying, warrants need to be in the money, more news coming..so we should be fine, however, the big question is where do they take it from here. This can be an 80 cent stock in a matter of a week or a few months. However, these guys maybe preparing for a run over the 1$ mark.
The amount of things in the pipeline for Alda are crazy, but one thing to remember is that they know what to run the ball and when to drop it. Therefore, look at last March's run as a potential (1.57), but never forget that we hit 6 cents a few monhs back.
MMN
Surf/Bouch,
I did sell some on the way up, but still sitting on my core, plus I have the PP paper and warrants coming this Jan.
Anyway, it seems that early 40's is an old story and now we can base in the late 40's early 50's till we get news or someone starts noticing us and buys a couple of million shares.
I wonder why they have not yet posted their Q2 results, which should show us what sales they made and how they are looking in terms of margins.
As for further details in the news, we will not get that. Scott told me several times that they will not put out the details of such contracts for confidintiality reasons.
I believe that there alot of reasons for this to trade at another level (70-80 level), especially that they have 2.7m of wearrants in the money at 45 and would expire by Nov 22nd.
Let's see who signs up next, maybe the Shoppers news will be our Christmas gift...lol
MMN
I hear they are building inventory before starting to announce deals, so when they say they are in XXX you would be able to find their product.
Hope TO excutes right and I see no issue with a 1$ by the end of this year.
MMN
Surf,
Now I will buy u a vacation once so that we can hit 1$...lol
Can you please post an updated chart and some TA comments.
MMN
VANOC’s $3-million to $15-million supplier category
"Earlier this year, VANOC signed two publicly-traded companies that each claim to have products that affect H1N1. One, Afexa Life Sciences, is the maker of a cold and flu remedy called COLD-FX. The other, ALDA Pharmaceuticals, was named the official supplier of hand sanitizer and disinfectant cleaning products. Both companies were signed to VANOC’s $3-million to $15-million supplier category. They each will provide quantities of their products for distribution to athletes, officials and other members of the Olympic family.
ALDA claims independent tests have shown its signature T36 Antiseptic Hand Sanitizer will “completely kill the new H1N1 virus . . . in 15 seconds or less.”
Gustafson, however, said regular handwashing with warm water and soap is just as effective as using alcohol-based hand sanitizers.
Handwashing: the new Olympic sport in the age of H1N1.
jefflee@vancouversun.com"
Drumstick,
You will learn by time that breaking up through old resistance that was created at the 30-40 will be the hardest part, but once it does this will easily run to a 1$ on sales news.
Another factor to consider is the PP, once this closes you will see a different spin on things.
MMN
Hey SurfinNj,
Can you give us a TA update on this one. It seems overbought, but this might be a break-out signal??
Thanks,
MMN
I think that once they start getting sales, which might be sooner than many think, the share price will be heading towards the 1.00$ mark.
Knowing how they ran this in early 2008, I can see no hard time getting this above the buck again and I am sure we will see some more US buying into this story along side.
MMN
I thought that was you Drum...lol
Drum from now till year end you will be able to sell at a doublw from here at least, so f you waited this long you should stick around for some promotion in the coming few months.
You need to remember that TO has alot of experiance in the junior market, he has Eugene on Board who is on the board of a major junior financing Co. So bottom line they will get this to higher levels when needed to raise funds at decent terms.
MMN
I found it to be a good news, but no BBs were talking about it. Also Anonymous was on the buy, so maybe they are starting to get some new hands into this.
MMN
I am not a believer in TA when it comes to Biotech stories, reason is quite simple. One news release may mean 100% and if I had followed TA last year this was overbought all the way from the 40's to the 1.50.
I made a small trade on Alda this year, by selling at 47 again not because if TA, because the SP went up on fear from Swine Flu.
I sold last year at 90-1.00, because I thought that was a fair price including promotion factors. This year might be different, but I also plan on taking profit on half of my position, when I see the price is right.
Bottom line is that TA reminds me not to fall so much in love with a story and to take profits.
I believe that we still can see some downside from here, but I do not think it will be for long.
MMN
30 cent warrants
After having a quick discussion with Terry today, he believes that the latest drop in the SP is due to warrants from shareholders that did the private placement of 2007. Those expire on the 7th of June and had an exercise price of 30 so he is guessing that sold last run were those who had them.
MMN
"Concerning the options, we insiders exercised 1,150,000 options at 12 cents. In the insider reporting on SEDI, it's a 2-step process.
First, we have to "dispose" of the options using the category, "51 - Exercise of options".
Second, we have purchase the shares also using same category, "51 - Exercise of options".
It looks like we "sell" the options and buy the shares. It's not just a simple conversion. The bureaucrats who designed the insider reporting system seem to have made it as complicated as possible.
Regards,
Terry"
May 12/09 May 03/09 Zokol, Ronald Direct Ownership Common Shares 51 - Exercise of options 50,000 $0.120
May 12/09 May 03/09 Zokol, Ronald Direct Ownership Options 51 - Exercise of options -50,000 $0.120
May 12/09 May 03/09 Allison, Linda J. Direct Ownership Common Shares 51 - Exercise of options 200,000 $0.120
May 12/09 May 03/09 Allison, Linda J. Direct Ownership Options 51 - Exercise of options -200,000 $0.120
May 12/09 May 03/09 Owen, Terrance G. Direct Ownership Common Shares 51 - Exercise of options 300,000 $36,000.000
May 12/09 May 03/09 Owen, Terrance G. Direct Ownership Options 51 - Exercise of options -300,000 $0.120
May 11/09 May 04/09 Chen, Peter Direct Ownership Common Shares 51 - Exercise of options 300,000 $0.120
May 11/09 May 04/09 Chen, Peter Direct Ownership Options 51 - Exercise of options -300,000 $0.120
Peter exercises 300k of options, S/O up 600k
May 11/09 May 04/09 Chen, Peter Direct Ownership Common Shares 51 - Exercise of options 300,000 $0.120
May 11/09 May 04/09 Chen, Peter Direct Ownership Options 51 - Exercise of options -300,000 $0.120
In responce to the Soapopular, Terry sent me the following email:
"Ours has 70% ethanol, which is a VERY effective anti-microbial. Theirs is water-based. I find water-based sanitizers are yucky and a gimmick. Do you want to kill the bugs? An ethanol base is the best way to go. Is there a problem with alcohol? Not that I know of.
TO"
ALDA EXPANDS MARKETING EFFORTS AND APPOINTS ACCOUNT MANAGER
Alda appoints Mann as account manager
2009-05-11 13:38 ET - News Release
Mr. Terrance Owen reports
ALDA EXPANDS MARKETING EFFORTS AND APPOINTS ACCOUNT MANAGER
Alda Pharmaceuticals Corp. has named Diane Mann to the new position of account manager.
Ms. Mann received her BSc in general science, with emphasis on biochemistry and microbiology, from the University of Manitoba in 1989. With nearly 20 years of experience in the brokerage, investment, communications, direct sales and investor relations businesses, Diane brings a solid understanding of sales, marketing and communications.
Dr. Terrance Owen, president and chief executive officer, states: "We are excited to have Diane join our team as we start implementing our marketing program. We have many untapped markets for our products and new ideas are coming to us all the time. We have done test marketing in selected pharmacies and the results have been very encouraging. We now intend to pursue sales in areas we have not previously served, such as banks, casinos, offices, sports teams, restaurants, travel agents and many other avenues. Now that we have more products for personal use and commercial use, it is time to seek new outlets for our products and provide additional support to all of our distributors".
The products available at this time include: disinfectant, disinfectant wipes, antiseptic hand sanitizer gel, antiseptic hand sanitizer wipes, disinfectant cleaner concentrate.
Additional products that are in progress include antiseptic hand sanitizer liquid and T36 DisinfexTM disinfectant cleaner.
"Those than can, do. Those that can't, teach. Those that can't teach, criticize.
It's a step forward. It's a brick in the wall. We can sell some product more quickly. This is bad news? Oh my. An opportunity becomes a problem ...... again!
Purell is owned by Pfizer. Pfizer has built a wall. Pfizer can be purchased for around $14 US now. Hmmmm ... ALDA at $0.35 or Pfizer at $14? What to do? What to do?
Is the glass half empty or is the glass half full? I think it's half full. Your worthy correspondent thinks it's half empty. If we get Shopper's, he'll think we should have signed up Walmart. If we get Walmart, he'll think we should have signed up Costco. Some people will NEVER be happy.
Too bad. So sad.
TO"
I heard that this week is very important in Toronto, besides the DTA, there will be the biggest financial meeting for biotechs.
I am not in Toronto and do know if Alda is setting some meetings, but sure hope so.
On another note, it would be nice if anyone who visited the DTA can share what he saw.
MMN
Hi Janet:
I own MDG as well, however, MDG's real milestone will be when/if they pass level 1.
Meanwhile, APH is steps away from having their product on the shelves for commercial purposes.
So if we talk share price, APH has a better potential of breaking out during the few weeks coming relative to MDG.
MMN
Swine Flu Increases Demand for Face Masks, Antivirals (Update2)
Share | Email | Print | A A A
By Carol Wolf
April 28 (Bloomberg) -- Drug stores are buying more antiviral drugs and hand sanitizers while makers of face masks are increasing production to meet growing demand as concerns rise over the spread of swine flu.
CVS Caremark Corp., Rite Aid Corp. and A.S. Watson Group placed additional orders for Roche Holding AG’s drug Tamiflu, while 3M Co. and Alpha Pro Tech Ltd. are making more face masks. Matsumotokiyoshi Holdings Co. is boosting supplies of sanitizers, soaps and masks.
The companies stand to benefit from increased sales of items that help prevent and treat what may become a global outbreak as swine flu cases in the U.S. doubled to 40 and Mexico’s toll of flu-related deaths reached as many as 149. The World Health Organization has raised its pandemic alert level because of the growing threat.
“If we continue to see a steady stream of news and this becomes a fixation issue with the public, this could have a substantial effect on companies,” said Peter Sorrentino, a senior fund manager at Cincinnati-based Huntington Asset Advisors Inc. “These are very low-cost, high-margin items.” Huntington overseas about $13.3 billion in assets.
Flu Strains
CVS Caremark, the biggest U.S. drug-store chain, said sales of face masks rose on its Web site on growing concern about the spread of swine flu in the U.S. The company, based in Woonsocket, Rhode Island, also has ordered more Tamiflu as prescriptions for the drug climb, said Michael DeAngelis, a CVS spokesman.
Walgreen Co., the second-largest U.S. drug-store chain has seen an increase in sales of masks and is “well stocked on Tamiflu,” said Tiffani Washington, a spokeswoman for the Deerfield, Illinois-based company.
CVS Caremark rose 94 cents, or 3.2 percent, to $30.86 at 11:47 a.m. in New York Stock Exchange composite trading. It had increased 4.1 percent this year before today. Walgreen gained 77 cents, or 2.6 percent, to $30.02; the shares had climbed 19 percent through yesterday.
Swine flu is a respiratory disease of pigs caused by type-A influenza that regularly leads to outbreaks among the animals, according to the Atlanta-based Centers for Disease Control and Prevention. Three main human flu strains circulate and cause 250,000 to 500,000 deaths a year in seasonal epidemics, according to the WHO.
There is no vaccine for the virus. Homeland Security Secretary Janet Napolitano said 25 percent of “courses of treatments” of drugs, known as antivirals, were being released from U.S. stockpiles. In all, there are 50 million courses, she said. Among those are Tamiflu, sold by Roche, based in Basel, Switzerland, and Relenza, from GlaxoSmithKline Plc of London.
Hong Kong, Singapore
Hong Kong’s General Chamber of Pharmacy Ltd., an organization of more than 200 small drug stores, said most members have sold all their stocks of face masks. A.S.Watson, a unit of Hutchison Whampoa Ltd. with 150 outlets in Hong Kong, said it’s seen a surge in demand for the masks.
An A.S. Watson outlet in the Singapore airport has seen demand for face masks jump 10 times and the company is stocking up on Tamiflu “in anticipation of greater demand,” said marketing manager Irene Lau. The chain has about 1,600 outlets across Asia.
An outbreak of severe acute respiratory syndrome, or SARS, killed 299 people in Hong Kong in 2003, forcing people to wear face masks when going outdoors. Travel to Asia plunged during the SARS outbreak, which killed 770 people worldwide.
Rite Aid, the third-largest U.S. drugstore chain, also added to its Tamiflu supply. Sales of personal-hygiene products have increased overall, particularly in New York and California, Cheryl Slavinsky, a spokeswoman for the Camp Hill, Pennsylvania- based company, said by telephone.
Matsumotokiyoshi, Clorox
“If SARS is any indication, you would see cleaning products like soaps do well,” said Ali Dibadj, an analyst with Sanford C. Bernstein & Co. in New York.
Matsumotokiyoshi Holdings Co., Japan’s biggest drug retailer by sales, has been increasing supplies of sanitizers, soaps and masks “since the outbreak of a new form of bird flu last summer,” said spokesman Nobuharu Takahashi. “Prices of these products haven’t risen, but it may be a little difficult to keep them in stock.”
Clorox Co., based in Oakland, California, said it’s making more bleach to meet growing demand for disinfectant and is restricting travel to and from Mexico. It has pulled together a group of employees from distribution to manufacturing to coordinate flu-related efforts, said Michael Costello, general manager of Clorox Latin America and Europe.
Biological Contaminants
3M has stepped up worldwide production of respiratory masks in response to the swine flu outbreak, Jacqueline Berry, a spokeswoman for the St. Paul, Minnesota-based company, said in a telephone interview. “We are getting demand from government agencies and hospitals worldwide,” said Berry, declining to give production numbers.
The respirators shield the user from biological contaminants. They differ from regular face masks, which are designed to help prevent the spread of contaminants from an infected person. 3M makes the respirators in the U.S., Latin America, Europe and Asia, Berry said.
Crisis Response
Alpha Pro Tech, based in Markham, Ontario, has boosted production of masks designed to protect against the virus, Chief Executive Officer Al Millar said in a telephone interview. Swine flu is a particularly small virus that can penetrate many other types of masks, he said.
“We have a very nice stock of respiratory masks on the floor at Alpha” Millar added. “We certainly won’t have any problems with supply.” The filter material for the masks can take as long as six weeks to deliver even without a crisis, he said.
Wal-Mart Stores Inc. spokesman Greg Rossiter said the world’s largest retailer is monitoring the outbreak and declined to comment on the Bentonville, Arkansas-based company’s sales of antiviral drugs and personal-hygiene products.
Retailers and suppliers have used crises from hurricane Katrina in New Orleans to the SARS outbreak in Asia to hone their crisis-response procedures, said Mark Grayson, a spokesman for Rx Response, which coordinates distribution of medical supplies among government agencies, manufacturers and retailers.
To contact the reporter on this story: Carol Wolf in Washington at cwolf@bloomberg.net.
Last Updated: April 28, 2009 11:53 EDT
Swine Flu May Be Named Event of International Concern
By Jason Gale
April 25 (Bloomberg) -- The World Health Organization is set to declare the deadly swine flu virus outbreak in Mexico and the U.S. a global concern, potentially prompting travel advisories, said a person familiar with the matter.
An emergency committee of the WHO in Geneva will declare the outbreak “a public health event of international concern” in a teleconference that began at 4 p.m. today, said the person, who spoke on condition of anonymity because the meeting is confidential. In response, WHO Director-General Margaret Chan may raise the level of pandemic alert, which could lead to travel advisories aimed at curbing the disease’s spread.
Human-to-human spread of the previously unknown H1N1 swine influenza in Mexico and the U.S. is heightening concern that the virus may spark a pandemic. At least 68 people have died and more than 1,000 have fallen ill with flu-like symptoms around Mexico City in the past month, officials said. The outbreak has pandemic potential, Chan said.
“The situation is evolving quickly,” she said on a conference call with reporters today. “A new disease is by definition poorly understood. We do not yet have a complete picture of the epidemiology or the risk, including the possible spread. In the assessment of the WHO, this is a serious situation which must be watched very closely.”
The emergency committee will consider whether to declare the outbreak a matter of international concern, and whether to recommend travel advisories, Chan told journalists before the panel’s meeting.
Closing Theaters
There’s no sign the outbreak has spread beyond Mexico and the U.S., she said. Three main human flu strains -- H3N2, H1N1 and type-B -- circulate and cause 250,000 to 500,000 deaths a year in seasonal epidemics, according to the WHO. Pandemics occur when a novel influenza A-type virus, to which almost no one has natural immunity, emerges and begins spreading.
Mexico’s Social Security Institute shut all of the theaters and cultural centers it operates nationwide to avoid spreading the flu strain -- reminiscent of actions implemented during the 2003 SARS outbreak in Asia. Travel curbs imposed there damaged economies throughout the region, where that virus circulated most widely.
In Singapore, where 33 infected people died, gross domestic product shrank 11.4 percent in the second quarter of 2003 because of the severe acute respiratory syndrome.
Pandemic Threat
Swine flu was confirmed in 20 of the deaths so far in Mexico. Of 14 tissue samples tested from Mexico, half were a genetic match with the swine flu reported in eight people in California and Texas, the Atlanta-based Centers of Disease Control and Prevention said.
“We do not know whether this swine flu virus or some other influenza virus will lead to the next pandemic,” Richard Besser, the CDC’s acting director, told reporters yesterday on a teleconference. “Scientists around the world continue to monitor the virus and take its threat seriously.”
The new influenza strain, a conglomeration of genes from swine, bird and human viruses, poses the biggest threat of a large-scale flu pandemic since the emergence of the H5N1 strain that has killed millions of birds and hundreds of people, said William Schaffner, an influenza expert at Vanderbilt University School of Medicine in Nashville, Tennessee.
“It re-combined to create something totally new,” David Butler-Jones, Canada’s chief public health minister, told reporters yesterday. “How, when, or where it did that I don’t think we know. What it will lead to is impossible to predict.”
Alert System
WHO’s alert level is at level 3, meaning there is no, or very limited, human-to-human transmission of a potential pandemic virus. Officials at the agency have said the global spread of the H5N1 bird flu virus since 2003 has put the world closer to another influenza pandemic than at any time since 1968, when the last of the previous century’s three pandemics occurred.
WHO uses a six-step alert system to tell the world what preparations to take in response to a pandemic. Flu can spread quickly when a new strain emerges because no one has natural immunity and a vaccine takes months to develop. The 1918 Spanish Flu pandemic, which killed as many as 50 million people, began when an avian flu virus jumped to people, doctors said.
“These levels of pandemic alert are all signals for action,” said Malik Peiris, a professor of microbiology at the University of Hong Kong, who has studied influenza viruses for more than a decade. “Raising the level of alertness to influenza, especially in returning travelers, would be a relevant thing to do.”
Tracing the Spread
It’s premature to draw parallels between the current outbreak and the 1918 flu, Chan said.
Teams of disease investigators have been sent to California and Texas to trace how the malady has spread, and the U.S. offered to send scientists to Mexico, said the CDC’s Besser. U.S. hospitals are being asked to collect samples from patients with flu-like symptoms, said Schaffner, chief of preventive medicine at Vanderbilt, in a telephone interview yesterday.
“They are asking us who work in hospitals to go to our emergency rooms and our pediatric wards to gather specimens and start testing them,” Schaffner said. “This has a sense of urgency about it.”
Mexico’s government has closed schools, museums, movie theaters and libraries in Mexico City and surrounding areas until further notice, according to an e-mail from the National Arts and Culture Council. It’s also handing out free facemasks and extending the deadline for filing taxes until May 31, Jose Cordova, Mexico’s Health Minister, told reporters yesterday. A million doses of antiviral medicine are available for distribution, he said.
Twenty-four cases, including three deaths, have been reported in San Luis Potosi, in central Mexico, and four cases have been found in Mexicali near the border with the U.S., according to the WHO.
To contact the reporter on this story: Jason Gale in Singapore at j.gale@bloomberg.net
Last Updated: April 25, 2009 10:57 EDT
"Any volume of trading down south will take some time. However, now that we CAN trade, we can address our promotional needs. I alway saw the US listing as a long term benefit with a lot of work needing to be done. People have to have a reason to buy the stock and we will be doing what is required.
Regards,
TO"
ALDA LAUNCHING NEW PRODUCTS AT O.D.A. MEETING, APRIL 30, 2009
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, OTCBB:APCSF) (“the Company” or “ALDA”) announces that the Company’s representatives will be attending the 142nd Annual Spring Meeting (“ASM”) of the Ontario Dental Association (“ODA”) commencing on April 30, 2009. This meeting is the largest dental conference held in Canada and is taking place at the Metro Toronto Convention Centre. Joining over 275 other exhibitors at the ASM, ALDA will be presenting its new product line at Booth 241 to over 10,000 dentists and 25,000 dental staff.
The product line to be presented includes:
T36® Disinfectant
T36® Disinfectant Wipes
T36® Antiseptic Hand Sanitizer Gel
T36® Antiseptic Hand Sanitizer Wipes
T36® Disinfectant Cleaner CONCENTRATE
Additional products that will be introduced after the meeting include T36® Antiseptic Hand Sanitizer Liquid and T36 DisinfexTM Disinfectant Cleaner.
Dr. Terrance Owen, President & CEO, states, “We have been working towards a coordinated launch of all of ALDA ’s products at this show for some time. All the pieces have come together for us to undertake a major promotion of the Company products to the dental industry at this gathering. We want to move forward to other markets as soon as possible thereafter by bolstering our sales and marketing expertise and seeking out new distributors that can tackle all the other markets we see for the T36® technology”.
Delegates to the ASM are invited to visit ALDA at Booth 241 to meet with company representatives and receive samples of the new products.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and in the U.S. on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
Distribution & Sales Contact
Peter Chen
(604) 521- 8300 Ext. 3
peter_chen@aldacorp.com.
Alda Pharmaceuticals lists on OTC Bulletin Board
2009-04-20 09:50 ET - News Release
Mr. Terrance Owen reports
ALDA PHARMACEUTICALS CORP. SHARES LISTED ON OTCBB
Alda Pharmaceuticals Corp.'s common shares have been added to the OTC Bulletin Board system as of today's date and will trade under the symbol APCSF.
Alda's common shares are registered with the United States Securities and Exchange Commission (SEC) pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. Alda files annual reports on Form 20-F and other materials with the SEC through the EDGAR system. Registration of Alda's shares in the United States allows its shares to be solicited and traded by licensed brokers in the United States in compliance with SEC regulations and blue-sky requirements in various states in the United States.
Alda's securities filings with the SEC and Canadian Securities Administrators and are available on-line at EDGAR and SEDAR, respectively.
We seek Safe Harbor.
"Re: your phone call today.
FINRA response time is supposed to be 10 days. Prior to FINRA, the market had to go to his compliance department and prepare and file their documents with FINRA. There is a process here with a number of steps. We have done everything we are supposed to do and must wait. Everything is proceeding as quickly as it can, believe me.
The acquisition does not have to close until August 31, 2009. We don't have to have the $$$ in the bank until August 30, 2009. I see no need to speculate on timing, prices or anything. I can assure you that we are doing the work that needs to be done to consumate this transaction but, there are a lot of steps, a lot of work and as usual, we will remain very tight lipped until we have something to report.
Regards
TO"
ALDA PHARMACEUTICALS CORP.
TSX-V – APH APRIL 2 , 2009
ARTICLE OF INTEREST – GREEN DISINFECTANTS
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V)
President and CEO Dr. Terrance Owen comments “An obstacle in entering hospital supply chains has been competition from products that do not get the job done in the first place and are then may be further diluted to save costs. This approach has put patients at risk from many known and new strains of viruses and bacteria. Our products have been tested and shown to be more effective against these threats than a number of other products that may be cheaper or “greener”. The following article explains some of the problems with today’s accepted cleaning methods.”
Hospitals warned about 'green' cleaners
Superbug Worry
Tom Blackwell, National Post Published: Wednesday, April 01, 2009
The flood of new "green" cleaning products and disinfectants being used by Canadian hospitals are often ineffective in combatting infections that sicken thousands of patients a year, experts warn.
Concerned about the trend, the Quebec Health Ministry recently urged hospitals in the province to be sure that products marketed as ecologically safe will also keep surfaces clean -- and patients protected.
In a letter issued this year, the ministry cited a survey indicating that more than 70% of Quebec health care facilities are using such green solutions.
With little regulation in the area, many manufacturers are marketing products that are simply diluted versions of more traditional chemicals, and have limited cleaning power, microbiologists and industry spokesmen say.
The hospitals typically dilute disinfectants even further, said Dr. Richard Marchand, a medical microbiologist at the Montreal Heart Institute.
"Because it's already half concentration, their normal dilution would now bring it to one in 20, and the product is inactive. And this happens often. There is no control," said Dr. Marchand, who advises the Quebec government on such issues.
"Some hospitals are having difficulty in controlling their infection rates because of the change in products."
The fear -- not yet scientifically proven -- is that underpowered green products are making hospitals more susceptible to such pathogens as C. difficile and the Norwalk virus, infectious-disease specialists say.
"What that does is gives the infection-control professional,
the people on the front-line in hospitals, a certain false sense of security," said Syed Sattar, a microbiologist at the University of Ottawa who specializes in disinfectants.
"They are all busy individuals and don't have either the time or deeper understanding to be able to look at the product label or brochure to decipher what exactly it is saying, or not saying."
It is estimated that "nosocomial" infection -- microbes spread within a hospital -- claim 8,000 to 12,000 lives in Canada yearly, and hygiene within the facilities is considered a major factor.
Experts say the drive to make cleaners more environmentally friendly is an important one, noting that the gases released by products such as chlorine bleach can be harmful to both staff and patients.
More care and vigilance is needed, though, in ensuring the right green products are used, they argue.
The Groupement provincial de l'industrie du medicament -- an association of Quebec-based pharmaceutical companies -- raised the green-cleaner issue with Health Canada at a meeting in January, suggesting the department send its own warning to hospitals.
A spokesman for the department was not available for comment yesterday. Health Canada is planning beefed-up guidelines for antiseptic products, which would set out clearer requirements. But it only issued proposals for the new rules in November, and it is unclear when they might come into force.
"With Health Canada, everything is very slow," said Dr. Marchand, who also does work for a firm that makes medical disinfectants. "It takes an accident sometimes for them to act faster ... I would hope they will not need five or seven deaths to engage in this."
Meanwhile, the testing required for licensing of disinfectants now is often insufficient to prove their effectiveness in a real-world hospital situation, while many products are effective in killing bacteria, but useless against viruses, like Norwalk, said Prof. Sattar, who also works with disinfectant manufacturers.
Health Canada, though, is also planning to mandate more stringent testing, he said, which would put this country ahead of many others.
tblackwell@nationalpost.com
About ALDA Pharmaceuticals
ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
http://www.aldacorp.com
Distribution & Sales Contact
Peter Chen
(604) 521- 8300 Ext. 3
peter_chen@aldacorp.com.
Investor Relations Contact
Scott Young
604-288-7222
syoung@freeformcom.com
I actually believe you might be correct this time, as Terry has always said that Spring is when he prefers to folds his cards. For a few reasons:
1- New investors are taking positions before the summer
2- Most brokers are around at this time
3- The US listing (this is still the key)
From the last LOI NR we know that the DD will be done by the end of June, with a finalization in August, so my thought is that Alda would want to get new audiance now, clean the market and raise the SP. Then before June try to seal a few million share financing along with debt.
Hopefully the SEC will be kind to us this month.
MMN
He was referring to SH, so do not get ofended.
He also mensioned to me how SH posters can save there time by reading the MD&A.
"Hi XXXXX.
Thanks for your recent thoughts and analyses.
Recently I have had a look at the posts on the BB's and notice that the opinions are generally positive about the proposed acquisition. However, I do see some rather uninformed commentary, as usual.
Here are some ideas which anyone could figure out if they put a bit of thought into it.
Why would we pay $6 Million and 2 million shares? The news release states that the company has products, customers and revenues. Maybe we think it's worth it.
How are we going to pay $6 million when we have closer to $2 Million in the bank? Debt or equity or some combination are the ways to raise money.
Will we sell 40 million shares? Why would we do that now when we have 6 months to close the deal.
If the China news release is reviewed, anyone will see that He-Yi has the agreements for $2 Million in sales, not ALDA. ALDA gets a royalty.
The agreement is non-binding because a number of conditions need to be satisfied. Reading the news release clarifies those conditions. The company is obliged by securities laws to disclose the Letter of Intent.
A Norwalk like, virus, as explained in the news release, is a surrogate that is close to virus of interest. Norwalk is difficult to reproduce in cell culture, so Feline Calicivirus is an FDAapproved surrogate.
Cheers,
Terry"
Here is a summary of my phone call of Terry this morning:
- The deal is not final, TSX requires the Company to disclose of any LOI as soon as it happens.
- Financing the deal is going to take a lot of thought. Terry thinks that from now till June, many options will open: equity at reasonable prices as the Company gets its US listing it can try getting funds from down south along with pitching equity to local brokers as well. However, the deal might be a Combo of debt and equity, as one of Alda’s directors (Eugene) is on the board of a financing Company and they will work together on nailing the best deal for Alda’s shareholders.
- The next round of Therapeutic development requires CAD600k, payable over a few months, so there is no conflict in going through this deal and no further dilution
- Terry believes that this deal is important for Alda on the short and long term.
o First on the short term it allows the Company to start producing their products directly, with full control over quality, meanwhile, they will use synergies to have one distribution network, which results in better GM% for the combined Company. Moreover, the deal will get Alda to generate more $$ and be less reliant on the market for any funding.
o Long term the deal will enable Alda to conduct its manufacturing for its therapeutic products and because the facility is FDA approved, this would save Alda 6 to 12 months (Please note that therapeutic products could take 3 years to happen if ever)
Finally, this is what I will be doing with my Alda shares. I will sell 60-70% of my holdings when they put their products on the shelves of some big chains. The balance will be my lucky ticket for a few years if/when Terry gets his product approved by the FDA.
MMN
Put the product on the shelve then talk about this going up.
ALDA RECEIVES NEW DIN FOR T36TRADEMARK ANTISEPTIC HAND SANITIZER WIPES
Alda Pharmaceuticals Corp. has been issued a new DIN by Health Canada for its T36 antiseptic hand sanitizer wipes (02321947). This new product complements Alda's previously approved T36 antiseptic hand sanitizer gel (DIN 02314320) and T36 antiseptic hand sanitizer liquid (DIN 02321424) and allows the formulation to be manufactured and sold as wipes.
Compared to typical alcohol-based hand sanitizers, Alda's T36 antiseptic hand sanitizer is a unique formula with two active ingredients that provide faster action against a broader range of infectious organisms and offer a long-lasting residual effect.
Dr. Terrance Owen, president and chief executive officer states: "With three DIN's for the T36 antiseptic hand sanitizer and one for the T36 disinfex disinfectant cleaner (DIN 02314134), we now have four approved consumer products. Being able to offer these products separately or bundled together in various combinations provides a great deal of flexibility to our customers."
New website in the works
Seems like they are working on a new website:
http://web.aldacorp.com/
MMN